E Therapeutics : Issue of Equity

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Issue of Equity

1 August 2016, Oxford and Newcastle, UK:e-Therapeutics plc (AIM: ETX), the drugdiscovery company, announces the issue, pursuant to the Company's offer for the issued and to be issued share capital of Searchbolt Limited ('the Offer'), of 15,568 new ordinary shares.

The new ordinary shares were issued on 29 July 2016 at a price of 14.55 pence per share, this being the average of the closing mid-market price for the 30 business days ending on the day before the announcement of the Offer.

Application has been made to admit the 15,568 new ordinary shares to trading on AIM anddealings in the new ordinary shares are expected to commence on 8 August 2016.

Following admission the number of ordinary shares in issue in the Company will be 268,339,057. This figure may be used by shareholders as thedenominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in,e-Therapeutics plc under the Financial Conduct Authority's Disclosure and Transparency Rules.

Contacts:

e-Therapeutics plc Iain Ross, Chairman Steve Medlicott, Finance Director	Tel: [phone] www.etherapeutics.co.uk
Numis Securities Limited Michael Meade / Freddie Barnfield (Corporate Finance) James Black (Corporate Broking)	Tel: [phone] www.numis.com
Instinctif Partners Melanie Toyne Sewell / Jayne Crook / Emma Barlow	Tel: [phone] Email:[e-mail]

About e-Therapeutics plc

e-Therapeutics (AIM: ETX) is a drug discovery company with a proprietary discovery platform based on advances in network pharmacology and chemical biology.

The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and anti-infectives. The platform is highly productive, yielding multiple potent and selective molecules at a much higher rate and more quickly than is reported for conventional drug discovery.

e-Therapeutics has a variety of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFα; ETS2400, Hedgehog pathway inhibition and ETS5200, broad spectrum antivirals. The Company has recently completed a phase IIb clinical trial for ETS6103, a drug to treat major depressive disorder.

The Company is fully funded to advance its drug discovery programmes. It is based in Oxford and Newcastle, UK. For more information, visitwww.etherapeutics.co.uk.